Floatz logo

INTERFERON ALFA-2B

Neuroendocrine Tumor G2

National Cancer Institute (NCI)protein_peptidePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Neuroendocrine Tumor G2 cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Mayo Clinic
Phase 2/3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3BB
Eloxatin
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2/3BB

View all 44 →

Same molecule, other indications

INTERFERON ALFA-2B is also rated in:

melanomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Stage IV Renal Cell CancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →